港股異動 | 君實生物(1877.HK)漲約4% 宣佈與旺山旺水合作開發口服核苷類抗新冠病毒藥物
格隆匯10月5日丨君實生物(1877.HK)漲約4%,報40.35港元,總市值367億港元。君實生物昨日宣佈與旺山旺水合作開發口服核苷類抗新冠病毒藥物VV116,雙方將共同承擔VV116在全球範圍內的臨牀開發和產業化工作。VV116已分別向中國和烏茲別克斯坦藥品監管部門遞交了臨牀試驗申請,目前已在烏茲別克斯坦的臨牀試驗申請已獲批准。臨牀前研究顯示,VV116在體內外都表現出顯著的抗新冠病毒作用,且具有很高的口服生物利用度,將有望成為包括疫苗、抗體藥物在內的多種抗疫手段的有力互補。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.